Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study.

Background: Subcutaneous recombinant interferon-beta 1a (IFN-β1a SC) is indicated for treatment of relapsing multiple sclerosis (RMS); however, it is associated with development of flu-like syndrome (FLS) in 75% of patients. No recommendations are available on whether evening or morning administration could induce better or worse FLS.

Objective: Primary objective was to investigate whether morning administration of IFN-β1a 44 µg (Rebif) would affect the severity of FLS versus evening administration, in patients with RMS.

Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.

Background: Teriflunomide (TRF) and Dimethyl fumarate (DMF) are licensed drugs for relapsing-remitting Multiple Sclerosis (RRMS).

Objectives: We aimed to compare the rate and the time to discontinuation among persons with RRMS (pwRRMS), newly treated with TRF and DMF.

Materials And Methods: A retrospective study on prospectively collected data was performed in nine tertiary MS centers, in Italy.

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience.

Background: The aim of the study was to evaluate the achievement of 'no evidence of disease activity' (NEDA) over a 12-month period in a large multicenter population with relapsing remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) and teriflunomide (TRF) using a propensity-score adjustment.

Methods: A time-to-event method was used to determine the percentages of patients with RRMS (pwRRMS) in both groups achieving NEDA 3 (no relapses, no 12-week confirmed disability progression, and no new T2/gadolinium-enhancing brain lesions). We described the safety profile of the investigated drugs.

Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).

Background: The approval of Sativex for the management of multiple sclerosis (MS) spasticity opened a new opportunity to many patients. In Italy, the healthcare payer can be fully reimbursed by the involved pharma company with the cost of treatment for patients not responding after a 4 week (28 days) trial period (Payment by Results, PbR), and 50% reimbursed with the cost of 6 weeks (42 days) treatment for other patients discontinuing (Cost Sharing, CS). The aim of our study was to describe the Sativex discontinuation profile from a large population of spasticity treated Italian MS patients.

Determination of size, molecular weight, and presence of subunits.

The size or apparent molecular weight of a given protein may be the most cited distinguishing characteristic of the molecule. In addition to being the basis of many separation methods, the molecular weight, or simply molecular size, immediately provides the investigator with an idea of the complexity of the molecule, whether it is likely to be difficult to produce in quantity, and whether certain analytical methods are likely to be productive. Knowing whether the polypeptide of interest can self assemble or exists in a heterogeneous complex with other polypeptides may provide valuable information regarding biosynthesis or mechanism.

Baseline resolution of isobaric phosphorylated and sulfated peptides and nucleotides by electrospray ionization FTICR ms: another step toward mass spectrometry-based proteomics.

Electrospray ionization broadband FTICR mass spectrometry at a mass resolving power, m/delta m50% > or = 400,000 has achieved the first direct mass spectral resolution of phosphorylated and sulfated peptides (or nucleotides) of the same nominal mass. The elemental composition difference in each case is PH versus S (9.5 mDa), requiring a minimum mass resolving power ((m2 - m1)/ml) of 118,000 (C terminal amidated cholecystekinin fragment 26-33 (CCK-8), DY(PO3H2)MGWMDF-NH2 versus DY(SO3H)MGWMDF-NH2) or 65,400 (adenosine triphosphate vs 3-phosphoadenosine 5'-phosphosulfate).

Phase correction for collision model analysis and enhanced resolving power of fourier transform ion cyclotron resonance mass spectra.

Phase correction of FT-ICR data yields an absorption spectrum that offers a gain by up to a factor of 2 in mass resolving power (at half-maximum peak height), compared to conventional magnitude-mode display. That improvement is equivalent to doubling the applied magnetic field strength, without loss in signal-to-noise (S/N) ratio, provided that the time-domain data are padded with an equal number of zeroes before FFT. Our simple, visual, user-interactive algorithm quickly corrects for zero-order and first-order variation of phase with frequency.

N-substituted 2-isocyanoarylacetamides with antimicrobial activity.

In this study, N-substituted 2-formylaminoarylacetamides (3) were obtained by the Ugi four-component reaction between isocyanides (1), aldehydes (2), and ammonium formate. The reaction products (3) were dehydrated with POCl3/NEt3 to give the title compounds (4). The structure of the compounds 3 and 4 was confirmed by spectral data and elemental analysis.

Synthesis of N-substituted isocyanocarboxamides with antimicrobial activity.

The Ugi four-component condensation between isocyanides 1, cycloketones 2, and ammonium formate affords N-substituted formylaminocarboxamides 3 which are dehydrated with POCl3/NEt3 to give the title compounds 4. The structure of the compounds 3 and 4 was confirmed by spectral data and elemental analyses. In vitro tests of antibacterial activity showed that compounds 4 are ineffective against E.

New imidazole-5-carbohydroxamic acids with biological activity.

A series of 1-benzyl-2-arylthio (or heteroarylthio)-5-imidazolecarbohydroxamic acids (Va-e) was prepared starting from the corresponding imidazole-5-carboxylic acids IIIa-e via acid chlorides IVa-e. Tests of biological activity showed that compounds Va-e are fairly active against Escherichia coli and Candida albicans.

Imidazole derivatives with potential biological activity.

A series of 1-substituted imidazole-5-carbohydroxamic acids Ia, Ib and Ic were prepared from the corresponding 5-methoxycarbonyl imidazoles (IX) obtained by a univocal synthesis starting with the reaction of the amines (III) with ethylchloroacetate. On treatment of 4(5)-methoxycarbonyl imidazoles (XI) with alkylaryl halides (X), on the contrary, mixtures of 1-substituted-4(or 5)-methoxycarbonyl imidazoles were obtained that, when separated by thin-layer chromatography, gave the carbohydroxamic acids Ia, Ib, Id and Ie and IIa leads to f. The structure of the imidazole derivatives were obtained by means of IR, NMR and UV spectra.

Synthesis of sulphonamidoquinoline derivatives.

In a research for new antimicrobial agents effective in therapy a new series of sulphonamidoquinoline derivatives have been studied. Their molecules, have got the feature of both 1-alkyl-1,4-dihydro-4-oxopyridine-3-carboxylic acid and sulphonamides. The structure of such compounds has been confirmed by chemical and physico-chemical methods and their antimicrobial activity has been tested.